CDX-622

CDX-622 is a bispecific antibody developed by Celldex Therapeutics for the treatment of inflammatory and fibrotic disorders. It simultaneously targets two key pathways implicated in chronic inflammation by potently neutralizing thymic stromal lymphopoietin (TSLP), an alarmin that promotes Type 2 inflammation, and depleting mast cells via stem cell factor (SCF) starvation. SCF is essential for mast cell survival through activation of the KIT receptor, which plays a central role in mast cell activation, maturation, and tissue recruitment. By dual inhibition of TSLP and SCF, CDX-622 aims to reduce tissue mast cells and inhibit Type 2 inflammatory responses more effectively than single-target therapies. Preclinical studies have shown that CDX-622 preferentially inhibits soluble SCF over its membrane form, exhibits favorable pharmacokinetics similar to monoclonal antibodies, significantly reduces skin mast cell signatures in human explant models, and demonstrates a strong safety profile with no observed adverse effects at high doses in animal studies. A Phase 1 clinical trial evaluating safety, pharmacokinetics, and pharmacodynamics in healthy volunteers is ongoing[1][3][5][6][7][8][9].